NEWARK, N.J., Dec. 17, 2010 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral’s Ogiene and Ygiene products into its member hospital association.
The KHA, established in 1929, represents hospitals, related health care organizations, and integrated health care systems and is dedicated to sustaining and improving the health status of the citizens of Kentucky. The KHSC aims to provide its member hospitals with the cleanest health care facilities possible.
“Based upon the information presented to us, including test results and expert opinion, these products appear to have an application for our members to provide the cleanest possible health care facilities for their patients,” said Brian Brezosky, Sr. Vice President and COO of KHSC.
“We are excited to go to Kentucky with our team to make a full presentation on all of the possible applications and uses of BioNeutral’s products,” said Dr. Andy Kielbania, Chief Scientist of BioNeutral. “We look forward to introducing our products to the Kentucky Hospitals.”
This announcement continues to build on the momentum BioNeutral has achieved over the past several months . BioNeutral’s Ygiene and Ogiene product lines have received acclaim in both commercial and consumer circles, for their ability to kill dangerous microorganisms and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. Over the past month, BioNeutral has entered into an agreement with leading specialty pharmaceutical company DFB Pharmaceuticals, announced the successful results of a leading independent laboratory test for its Ygiene product line, and been recognized as an innovative company by leading business publication The Record.
About The Kentucky Hospital Association
The Kentucky Hospital Association (KHA), established in 1929, represents hospitals, related health care organizations, and integrated health care systems dedicated to sustaining and improving the health status of the citizens of Kentucky.
The KHA represents all hospitals in the Commonwealth of Kentucky. Annually they treat 6 million outpatients, 2 million emergency patients, 600,000 inpatients and bring 54,000 babies into the world. For more information see www.kyha.com
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral’s products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene brand has been submitted to the EPA for approval for sale in the United States, has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements
This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company’s filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company’s technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company’s data and findings. BioNeutral’s antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the UnitedStates.
SOURCE BioNeutral Group, Inc.
